Aktienanalyse zu Thermo Fisher Scientific Inc (TMO)TMOThermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies. It operates in the Healthcare sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Thermo Fisher Scientific Inc is a good buy right now, with a current price of $658.02 and a forward P/E ratio of 24.15, suggesting that the stock is reasonably valued for future growth. The stock has shown a strong year-to-date change of +11.06% and a 1-year change of +25.44%, indicating solid performance. However, the RSI is at 47.83, suggesting it is neither overbought nor oversold, which is favorable for new investors. The main risk is the debt to equity ratio, which stands at 80.76%, indicating a higher level of debt relative to equity, which could impact financial stability if not managed properly.

15 analysts cover TMO: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 658.89.